Impacting society, creating change
Technologies developed at Ohio State are changing the world. Learn more about the startups that are currently a part of the Ohio State portfolio or download our printable catalog (as of June 30, 2019).
Search for a Startup below
CytoImmune Therapeutics is commercializing a coordinated immunotherapy platform for cancer treatments that combines chimeric antigen receptors (CARs) and bispecific antibodies (biAbs) with T cells and natural killer cells. This technology reduces the patient’s time to personalized treatment and enables optimized dosing with limited off-target effects. The company is developing product candidates targeted at treating acute myeloid leukemia, glioblastoma and multiple myeloma.
Celenex is a clinical-stage gene therapy company bringing to market a portfolio of ten gene therapies licensed from Nationwide Children’s Hospital and The Ohio State University for treatments for lysosomal storage disorders. The company is initially targeting Batten disease, with therapies targeting CLN6, CLN3 and CLN8, as potential first-to-market curative therapies for these rare and devastating diseases. Celenex was acquired by Amicus Therapeutics in September 2018 for $100M upfront and $277M in potential downstream milestone payments.
AveXis is a biotechnology company developing gene therapies designed to treat rare and life-threatening neurological genetic diseases. The initial proprietary investigational gene replacement therapy, AVXS-101 (onasemnogene abeparvovec-xioi) is in development for the treatment of spinal muscular atrophy (SMA). In addition, the company is pursuing gene therapies for Rett syndrome (AVXS-201) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene (AVXS-301).
Aether Therapeutics develops new therapies for pain and addiction. The company is developing its lead compound, 6BMX, as a first-in-class treatment strategy for the prevention of neonatal abstinence syndrome (NAS). NAS affects infants born to mothers suffering from opioid addiction, a significantly increasing problem due to the opioid epidemic.
Sesame’s initial product is a middleware that resides between a database or distributed file system like Hadoop and a data visualization or business intelligence tool like Tableau, accelerating data returned from Structured Query Language (SQL) queries. Sesame intercepts a user query to understand and anticipate the next user query. Sesame solves data latency problems to save companies time and money, while improving user productivity.